MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    The Effect of Stochastic Resonance Stimulation in Neural Control of Balance During Walking in Parkinson Disease

    E. Alsaqabi, S. Dibianca, A. Sansare, K. Verma, J. Jeka, H. Reimann (Newark, USA)

    Objective: This study aimed to investigate the effect of stochastic resonance (SR) stimulation on balance control during visually perturbed walking in people with Parkinson disease…
  • 2024 International Congress

    Effect of Levodopa therapy in Hypokinetic Dysarthria in Parkinson’s Disease

    E. Smaoui, N. Farhat, S. Daoud, K. Moalla, N. Bouattour, M. Damak, C. Mhiri (Sfax, Tunisia)

    Objective: The objective of this study was to assess the possible changes in acoustic speech parameters in a cohort of PD patients after acute levodopa…
  • 2024 International Congress

    Effect of Prasinezumab on Parkinson’s Disease Motor Progression in a Long-term Open-label Extension of the PASADENA Trial

    G. Pagano, A. Monnet, A. Reyes, B. Ribba, H. Svoboda, T. Kustermann, T. Simuni, R. Postuma, N. Pavese, F. Stocchi, K. Brockmann, K. Smigorski, V. Gerbaldo, P. Fontoura, R. Doody, G. Kerchner, P. Brundin, K. Marek, A. Bonni, T. Nikolcheva (Basel, Switzerland)

    Objective: To evaluate the long-term effect of prasinezumab on motor progression, assessed as change in MDS-UPDRS Part III in OFF- and ON-state, and MDS-UPDRS Part…
  • 2024 International Congress

    Characterisation of the pharmacokinetic profile of amantadine in the common marmoset

    D. Bédard, F. Gaudette, S. Nuara, F. Beaudry, P. Huot (Montreal, Canada)

    Objective: To determine the pharmacokinetic (PK) profile of amantadine in the common marmoset (Callithrix jacchus). Background: Amantadine is currently approved for the treatment of L-3,4-dihydroxyphenylalanine…
  • 2024 International Congress

    Trends in Physiotherapy Interventions and Medical Costs for Parkinson’s Disease in South Korea, 2011–2020

    DW. Ryu, MJ. Lee, JS. Park, DL. Yoo, SM. Cheon ()

    Objective: We analyzed trends in PT interventions and associated medical costs among South Korean patients with PD between 2011 and 2020. Background: Physiotherapy (PT), an…
  • 2024 International Congress

    Efficacy and Safety of Controlled-Release Levodopa in Parkinson’s Disease: a Systematic Review and Meta-Analysis

    G. Bolner, Y. Rossi, E. de Almeida, F. de Oliveira, V. Müller, L. Barbosa Lima, A. Rossato, G. Guindani Maia, A. Hilbig (Porto Alegre, Brazil)

    Objective: To evaluate the efficacy and safety of controlled-release levodopa (CRLD) compared with standard release levodopa (SRLD) in patients with Parkinson’s Disease (PD) and motor…
  • 2024 International Congress

    The international validation of the “Stepped Care” toolkit for comprehensive real life clinical care: bridging massive unmet need in care of Parkinson’s disease.

    K. Poplawska-Domaszewicz, MA. Qamar, L. Batzu, A. Shalash, Y. Lau, C. Falup-Pecurariu, A. Rekik, I. Boura, C. Spanaki, J. Chacko, C. Rodriguez-Blazquez, D. Urso, R. van Coller, D. Trivedi, V. Leta, W. Kozubski, S. Michalak, J. Slawek, C. Padmakumar, S. Gangadharan, K. Koh, C. Lazacano-Ocampo, A. Sauerbier, H. Dafsari, Y. Tsuboi, N. Mostyn, K. Ray Chaudhuri (Poznan, Poland)

    Objective: To conduct a cognitive pretesting of a global, cross-cultural, multicentre (14 countries) Stepped Care clinical toolkit. The questionnaire is completed by the healthcare professional…
  • 2024 International Congress

    Opicapone Reduces Homocysteine Levels in Patients with Parkinson’s Disease Treated with Levodopa Gel Infusion

    M. Minar, I. Straka, Z. Kosutzka, Z. Andre (Bratislava, Slovakia)

    Objective: Our study aims to assess the effect of an add-on treatment with catechol-O-methyl transferase (COMT) inhibitor, opicapone, on the plasmatic levels of homocysteine (HCY)…
  • 2024 International Congress

    Association between statin use and mortality in Parkinson’s disease

    M. Park, I. Hong, M. Baek (Gwangmyeong, Republic of Korea)

    Objective: To investigate whether usage of statin is associated with decreased mortality in Parkinson’s disease (PD). Background: Large-scale genome sequencing studies of PD have identified…
  • 2024 International Congress

    iPLA2β controls ER-mitochondria tethering and Ca2+ transfer in Parkinson’s disease

    ZH. Lin, Y. Liu, NJ. Xue, BR. Zhang, JL. Pu (Hangzhou, China)

    Objective: In this study, we aimed to investigate whether Parkinson's disease (PD) associated calcium-independent phospholipase A2β (iPLA2β) regulates the integrity and functions of endoplasmic reticulum…
  • « Previous Page
  • 1
  • …
  • 263
  • 264
  • 265
  • 266
  • 267
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley